CA
NZ
UK
AU
IND
US
DENTSPLY SIRONA reported $898 million in net sales for the second quarter of 2026, representing a 4.1% decrease from $936 million in the same period last year. Despite this sales drop, the firm’s performance was strong against market expectations, with an adjusted EPS of …
This result surpassed analysts' estimates, contributing positively to investor sentiment. The company's earnings per share (EPS) was reported at $-0.14, slightly better than the consensus expectation of $-0.16. Growth was largely driven by stronger demand for portable oxygen concentrators, particularly in international markets, with …
This performance fell in line with the consensus estimate of a loss per share of $-0.02, yet overall investor sentiment turned sour, with shares plunging 14% to $0.66. Year-to-date, SkinHealth's stock has declined 52.8%, reflecting growing investor skepticism amid ongoing operational challenges.
Falling profits at Novo Nordisk have triggered a rating downgrade, with Q2 earnings tumbling 70%. This sharp decline reflects operational issues and increasing competition that threaten the company's previously dominant position in diabetes and obesity treatments, notably its top-selling drug, semaglutide. As analysts adjust …
United-Guardian delivered a 10% lift in second‑quarter net sales, reaching $3,108,267, and a 16% jump in net income to $728,579, pushing earnings per share to $0.16. The surge reflects a 44% rise in cosmetic ingredient sales and a modest 1% gain in pharmaceutical revenue, …
Canopy Growth's fiscal Q1 2027 revenue increased 13%, reaching C$81.2 million, a performance driven by growth across its cannabis and Storz & Bickel business segments. The company reported a narrowed adjusted EBITDA loss of 59%, bringing it down to C$3.2 million as management reiterated …
This move aligns with the company’s strategy to draw in talent essential for advancing its precision medicine initiatives in oncology, potentially boosting employee retention and company performance. As the stock options vest over four years, this structure encourages long-term commitment from new hires, important …
Nxera Pharma conducted its Q2 2026 earnings call on August 7, focusing heavily on growth strategies stemming from its commitment to innovation. The leadership team highlighted efforts to enhance its product pipeline, emphasizing a long-term vision to capitalize on emerging market opportunities. This shift …
This adjustment coincides with a shift from traditional debt obligations to revenue-linked payments, allowing the company to potentially enhance its financial flexibility and fund growth initiatives. The announcement marks an essential pivot in Verastem's financing strategy, coming at a time when the company needs …
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) achieved $254.6 million in worldwide sales during the second quarter of 2026, reflecting a 6% improvement from $240.7 million in the same quarter last year. This performance surpassed analyst expectations, as the reported earnings per share (EPS) came …
Please wait processing your request...